COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,169 Articles (22,703 medRxiv, 8,466 bioRxiv)

Most recent first Previous |  Page 585: Articles 5841-5850  | Next

The ACE-2 receptor accelerates but is not biochemically required for SARS-CoV-2 membrane fusion.
Cervantes, M., Hess, T., Morbioli, G. G., Sengar, A., Kasson, P. M.
10.1101/2022.10.22.513347 — Posted: 2022-10-24
Phenotypic alteration of low-density granulocytes in people with pulmonary post-acute sequalae of SARS-CoV-2 infection
Dean, L. S., Devendra, G., Jiyarom, B., Subia, N., Tallquist, M. V., Nerurkar, V. R., Chang, S. P., Chow, D. C., Shikuma, C. M., Park, J.
10.1101/2022.10.22.513351 — Posted: 2022-10-24
Antibody avidity and multi-specificity combined to confer protection against SARS-CoV-2 and resilience against viral escape
Burn Aschner, C., Muthuraman, K., Kucharska, I., Cui, H., Prieto, K., Nair, M. S., Wang, M., Huang, Y., Christie-Holmes, N., Poon, B., Lam, J., Sultana, A., Kozak, R., Mubareka, S., Rubinstein, J. L., Rujas, E., Treanor, B., Ho, D. D., Jetha, A., Julien, J.-P.
10.1101/2022.10.23.513379 — Posted: 2022-10-24
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
Patel, A., Kumar, S., Lai, L., Chakravarthy, C., Valanparambil, R., Reddy, E. S., Gottimukkala, K., Bajpai, P., Raju, D. R., Edara, V. V., Davis-Gardner, M. E., Linderman, S., Dixit, K., Sharma, P., Mantus, G., Cheedarla, N., Verkerke, H. P., Frank, F., Neish, A. S., Roback, J. D., Davis, C. W., Wrammert, J., Ahmed, R., Suthar, M., Sharma, A., Murali-Krishna, K., Chandele, A., Ortlund, E. A.
10.1101/2022.10.24.513517 — Posted: 2022-10-24
Vaccine- and BTI-elicited pre-Omicron immunity more effectively neutralizes Omicron sublineages BA.1, BA.2, BA.4 and BA.5 than pre-Omicron infection alone
Santos da Silva, E., Servais, J.-Y., Kohnen, M., Arendt, V., Gilson, G., Staub, T., Seguin-Devaux, C., Perez-Bercoff, D.
10.1101/2022.10.24.513415 — Posted: 2022-10-24
Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot
Wang, Q., Bowen, A., Valdez, R., Gherasim, C., Gordon, A., Lihong, L., Ho, D. D.
10.1101/2022.10.22.513349 — Posted: 2022-10-24
Modulation of type I interferon responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus macaques
Hoang, T. N., Viox, E. G., Upadhyay, A. A., Strongin, Z., Tharp, G. K., Pino, M., Nchioua, R., Hirschenberger, M., Gagne, M., Nguyen, K., Harper, J. L., Marciano, S., Boddapati, A. K., Pellegrini, K. L., Tisoncik-Go, J., Whitmore, L. S., Karunakaran, K. A., Roy, M., Kirejczyk, S., Curran, E. H., Wallace, C., Wood, J. S., Connor-Stroud, F., Kasturi, S. P., Levit, R. D., Gale, M., Vanderford, T. H., Silvestri, G., Busman-Sahay, K., Estes, J. D., Vaccari, M., Douek, D. C., Sparrer, K. M. J., Kirchhoff, F., Johnson, R. P., Schreiber, G., Bosinger, S. E., Paiardini, M.
10.1101/2022.10.21.512606 — Posted: 2022-10-24
Comparison of COVID-19 Home-Testers vs Laboratory-Testers in New York State (Excluding New York City), November 2021 to April 2022
Dorabawila, V., Barnes, V., Ramesh, N., Hoen, R., Sommer, J., Robbins, A., Backenson, B., Lutterloh, E., Hoefer, D., Rosenberg, E.
10.1101/2022.10.21.22281319 — Posted: 2022-10-24
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England
Harman, K., Nash, S. G., Webster, H. H., Groves, N., Hardstaff, J., Bridgen, J., Blomquist, P. B., Hope, R., Ashano, E., Myers, R., Rokadiya, S., Hopkins, S., Brown, C. S., Chand, M., Dabrera, G., Thelwall, S.
10.1101/2022.10.21.22281171 — Posted: 2022-10-22
Impact of the COVID-19 pandemic on the circulation of other pathogens in England
Hayes, L., Uri, H., Bojkova, D., Cinatl, J., Wass, M. N., Michaelis, M.
10.1101/2022.10.21.22281366 — Posted: 2022-10-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).